Production (Stage)
CytomX Therapeutics, Inc.
CTMX
$2.74
-$0.01-0.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 24.63% | 229.08% | 187.79% | -147.38% | 1,547.67% |
| Total Depreciation and Amortization | -6.78% | -3.73% | -6.54% | -1.71% | -3.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.59% | 25.07% | 24.36% | 41.48% | -20.39% |
| Change in Net Operating Assets | -14.79% | -44.44% | -92.28% | 63.88% | -68.17% |
| Cash from Operations | -5.70% | 3.96% | -6.04% | 24.94% | -18.59% |
| Capital Expenditure | -48.75% | -321.05% | 80.21% | 16.52% | 56.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 101.87% | -16.34% | -15.83% | -51.98% | 242.67% |
| Cash from Investing | 102.15% | -16.69% | -15.54% | -52.07% | 248.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 2,830.46% | -28.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | 2,830.46% | -28.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 478.49% | 1.44% | -136.26% | -62.86% | 314.77% |